摘要
【目的】分析通腑醒神胶囊对脑出血患者临床疗效的影响。【方法】采用回顾性研究方法,收集2019年5月至2020年5月在广东省中医院脑病中心住院治疗的320例急性脑出血患者的临床资料,根据是否使用通腑醒神胶囊分为对照组154例和通腑组166例。对照组给予常规西药治疗,通腑组在常规西药治疗基础上联合通腑醒神胶囊治疗。比较2组患者治疗后的死亡率、良好预后率[改良Rankin量表(m RS)评分≤2分]及卒中相关性肺炎(SAP)发生率、严重程度和病死率情况。【结果】(1)治疗后,通腑组的病死率为9.0%(15/166),对照组为18.8%(29/154),组间比较,通腑组的病死率明显低于对照组(P<0.05)。(2)治疗后,通腑组的良好预后率为39.8%(66/166),对照组为29.2%(45/154),组间比较,通腑组出院时的良好预后率高于对照组(P<0.05)。(3)对SAP患者进行亚组分析:治疗后,通腑组的SAP发生率为36.7%(61/166),对照组为42.2%(65/154),组间比较,通腑组的SAP发生率略低于对照组,但差异无统计学意义(P>0.05);通腑组患者的SAP病死率为9.8%(6/61),对照组为27.7%(18/65),组间比较,通腑组患者的SAP病死率明显低于对照组(P<0.05);通腑组SAP患者的临床肺部感染评分(CPIS)为6.0(4.5-7.0)分,对照组为6.0(5.0-7.5)分,组间比较,通腑组SAP患者的CPIS评分低于对照组(P<0.05)。【结论】对于脑出血患者,在常规西药治疗基础上加用通腑醒神胶囊,可以显著降低死亡率,改善患者预后,并且能够降低SAP患者死亡率及严重程度。
Objective To analyze the clinical efficacy of Tongfu Xingshen Capsule for the treatment of intracerebral hemorrhage(ICH).Methods A retrospective study was adopted.The clinical data of 320 patients with acute ICH hospitalized in the Encephalopathy Center of Guangdong Provincial Hospital of Traditional Chinese Medicine from May 2019 to May 2020 were collected.The patients were divided into control group(154 cases)and Tongfu group(166 cases)according to the medication of Tongfu Xingshen Capsule or not.The control group was treated with conventional western medicine,and the Tongfu group was treated with Tongfu Xingshen Capsule together with conventional western medicine.The mortality and good prognosis rate[defined as modified Rankin scale(mRS)score≤2 points]as well as the incidence,severity and mortality of stroke-associated pneumonia(SAP)were compared between the two groups after treatment.Results(1)After treatment,the mortality of Tongfu group was 9.0%(15/166)and that of the control group was 18.8%(29/154).The intergroup comparison showed that the mortality of Tongfu group was significantly lower than that of the control group(P<0.05).(2)After treatment,the good prognosis rate of Tongfu group was 39.8%(66/166)and that of the control group was 29.2%(45/154).The intergroup comparison showed that the good prognosis rate of Tongfu group was higher than that of control group(P<0.05).(3)Subgroup analysis of SAP patients showed that SAP incidence rate in the Tongfu group was 36.7%(61/66),and was Mildly lower than that in the control group[42.2%(65/154)],the difference being insignificant(P>0.05).SAP mortality was 9.8%(6/61)in the Tongfu group and was 27.7%(18/65)in the control group after treatment.The intergroup comparison showed that the SAP mortality in Tongfu group was significantly lower than that in the control group(P<0.05).The clinical pulmonary infection score(CPIS)of SAP patients in Tongfu group was 6.0(4.5-7.0)points,and that in the control group was 6.0(5.0-7.5)points.The intergroup comparison showed that t
作者
杜雅明
李惠平
郭建文
王立新
卢鸿基
DU Ya-Ming;LI Hui-Ping;GUO Jian-Wen;WANG Li-Xin;LU Hong-Ji(The Second Clinical Medical School of Guangzhou University of Chinese Medicine,Guangzhou 510405 Guangdong,China;Dept.of Neurocritical Care,Guangdong Provincial Hospital of Traditional Chinese Medicine,the Second Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou 510120 Guangdong,China)
出处
《广州中医药大学学报》
CAS
2022年第5期1002-1006,共5页
Journal of Guangzhou University of Traditional Chinese Medicine
基金
国家自然科学基金项目(编号:81974559)
广东省重点领域研发计划资助项目(编号:2020B1111100009)
广东省中医药局科研项目(编号:20202076)
关键词
通腑醒神胶囊
脑出血
卒中相关性肺炎
临床疗效
回顾性分析
Tongfu Xingshen Capsule
intracerebral hemorrhage(ICH)
stroke-associated pneumonia
clinical efficacy
retrospective analysis
